Published in J Infect Dis on August 30, 2006
A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res (2010) 1.82
Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One (2011) 1.80
Evolution and taxonomic classification of alphapapillomavirus 7 complete genomes: HPV18, HPV39, HPV45, HPV59, HPV68 and HPV70. PLoS One (2013) 1.07
p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes. J Virol (2011) 0.89
Lineages of oncogenic human papillomavirus types other than type 16 and 18 and risk for cervical intraepithelial neoplasia. J Natl Cancer Inst (2014) 0.87
Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer. Virology (2013) 0.85
Human papillomavirus type 16 variants in paired enrollment and follow-up cervical samples: implications for a proper understanding of type-specific persistent infections. J Infect Dis (2010) 0.85
Genetic variations of E6 and long control region of human papillomavirus type 16 from patients with cervical lesion in Liaoning, China. BMC Cancer (2013) 0.81
Comparison of p53 and the PDZ domain containing protein MAGI-3 regulation by the E6 protein from high-risk human papillomaviruses. Virol J (2008) 0.79
Variants of human papillomavirus type 16 predispose toward persistent infection. Int J Clin Exp Pathol (2015) 0.77
Ano-genital human papillomavirus type 97 infection is detected in Canadian men but not women at risk or infected with the human immunodeficiency virus. Virol J (2012) 0.75
E6 and E7 Gene Polymorphisms in Human Papillomavirus Types-58 and 33 Identified in Southwest China. PLoS One (2017) 0.75
Human papillomavirus variants among Inuit women in northern Quebec, Canada. Int J Circumpolar Health (2015) 0.75
Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med (2007) 9.53
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet (2004) 8.09
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet (2011) 4.70
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev (2008) 3.93
Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst (2012) 3.87
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS (2003) 3.60
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
The epidemiology of genital human papillomavirus infection. Vaccine (2006) 3.28
Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet (2013) 3.25
Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis (2012) 3.25
Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis (2011) 3.16
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine (2006) 2.95
Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol Oncol (2007) 2.90
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine (2007) 2.64
The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev (2003) 2.52
Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine (2006) 2.51
Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol (2007) 2.49
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine (2008) 2.48
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory‐confirmed secondary attack rates and evidence of asymptomatic infections. Clin Infect Dis (2010) 2.41
Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev (2006) 2.39
Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med (2007) 2.35
The influence of light at night exposure on melatonin levels among Canadian rotating shift nurses. Cancer Epidemiol Biomarkers Prev (2011) 2.27
Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. J Clin Oncol (2014) 2.25
Increased risk of breast cancer associated with long-term shift work in Canada. Occup Environ Med (2013) 2.24
Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol (2002) 2.18
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol (2004) 2.01
Delays in diagnosis and treatment among children and adolescents with cancer in Canada. Pediatr Blood Cancer (2008) 1.98
HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis (2011) 1.95
The epidemiology of oral HPV infection among a multinational sample of healthy men. Cancer Epidemiol Biomarkers Prev (2010) 1.94
Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol (2012) 1.94
Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS (2008) 1.89
Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis (2009) 1.89
Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med (2011) 1.89
Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst (2003) 1.84
Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J Infect Dis (2011) 1.84
Reestablishment of damaged adult motor pathways by grafted embryonic cortical neurons. Nat Neurosci (2007) 1.83
Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer (2003) 1.78
Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis (2008) 1.72
CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. J Virol (2003) 1.72
Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine (2007) 1.71
Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec. J Infect Dis (2011) 1.70
Management of low-grade cervical lesions in young women. CMAJ (2005) 1.69
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer (2010) 1.65
Prosthetic hip joint infection with a Streptococcus agalactiae isolate not susceptible to penicillin G and ceftriaxone. J Antimicrob Chemother (2009) 1.65
Assessing the gain in diagnostic performance when combining two diagnostic tests. Stat Med (2002) 1.65
Performance of an agar dilution method and a Vitek 2 card for detection of inducible clindamycin resistance in Staphylococcus spp. J Clin Microbiol (2010) 1.56
Proliferative and nonproliferative lesions of the rat and mouse respiratory tract. Toxicol Pathol (2009) 1.53
Reproductive health of adolescent girls perinatally infected with HIV. Am J Public Health (2007) 1.53
Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol (2006) 1.53
Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res (2010) 1.50
High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer (2007) 1.47
Diagnosis delays in childhood cancer: a review. Cancer (2007) 1.44
Consistent condom use reduces the genital human papillomavirus burden among high-risk men: the HPV infection in men study. J Infect Dis (2013) 1.43
Comparison of the A2 gene locus in Leishmania donovani and Leishmania major and its control over cutaneous infection. J Biol Chem (2003) 1.42
Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: the HPV in men study. J Infect Dis (2011) 1.40
Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study). Cancer Epidemiol Biomarkers Prev (2011) 1.37
Biological validation of self-reported condom use among sex workers in Guinea. AIDS Behav (2009) 1.34
Human papillomavirus infection and oral cancer: a case-control study in Montreal, Canada. Oral Oncol (2007) 1.34
Methylation of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression? Virology (2006) 1.33
Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev (2005) 1.32
Predictors of cervical coinfection with multiple human papillomavirus types. Cancer Epidemiol Biomarkers Prev (2003) 1.31
Making prospective registration of observational research a reality. Sci Transl Med (2014) 1.31
Screening for diabetic retinopathy in James Bay, Ontario: a cost-effectiveness analysis. CMAJ (2003) 1.31
Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities. Sex Transm Dis (2003) 1.30
Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. Cell Mol Life Sci (2010) 1.29
p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev (2004) 1.26
Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: the interface with social factors and service utilization. Addiction (2004) 1.26
Ciprofloxacin-resistant Shigella sonnei among men who have sex with men, Canada, 2010. Emerg Infect Dis (2011) 1.26
The prevalence of genital HPV and factors associated with oncogenic HPV among men having sex with men and men having sex with women and men: the HIM study. Sex Transm Dis (2011) 1.24
International proficiency study of a consensus L1 PCR assay for the detection and typing of human papillomavirus DNA: evaluation of accuracy and intralaboratory and interlaboratory agreement. J Clin Microbiol (2003) 1.23
Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis. Int J Cancer (2012) 1.23
Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16. J Virol (2005) 1.22
Determinants for the development of visceral leishmaniasis disease. PLoS Pathog (2013) 1.22
Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. Int J Cancer (2006) 1.22